Clinerion was selected by the Swiss Personalized Health Network to be the backbone of its Federated Query System due to the nature of its patented federated cloud infrastructure, which allows patient data to remain inside the IT infrastructure and under the control of each hospital, while still allowing queries of anonymized and obfuscated patient data from other hospitals in the network.
The five university hospitals of Switzerland are:
The FQS allows researchers to verify the feasibility of their project by assessing whether suitable patient data for specific research questions exist at Swiss university hospitals. The available information in the system, currently more than 70 million data elements from over 450’000 patients, who have consented to the further use of their data for research purposes, is a subset of the clinical data of all five university hospitals.
The platform includes demographic data (age and gender), diagnosis (coded in ICD-10), procedures (coded in CHOP), medication (coded in ATC), laboratory tests (coded in LOINC) and laboratory test results with units (according to UCUM). Under the project lead of the SPHN Data Coordination Center (DCC) managed by the SIB Swiss Institute of Bioinformatics, the clinical partners harmonized and standardized the anonymized clinical information, making it available for federated queries via a common front-end.
The FQS uses a customized version of Patient Network Explorer, enabling researchers to search for fully anonymized clinical information across all five university hospitals, while allowing the hospitals to retain full control over their data. It fully complies with privacy requirements, since only aggregated search results are shared with users and small patient numbers are obfuscated to prevent potential re-identification.
Clinerion Patient Network Explorer Technology Used by the Swiss Personalized Health Network
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.